<DOC>
	<DOCNO>NCT01380990</DOCNO>
	<brief_summary>Adenosine Deaminase ( ADA ) enzyme , need body develop lymphocytes immune system . Children born mutation mutation ADA gene severe combine immunodeficiency ( SCID ) . Children ADA-deficient SCID generally die first year life severe infection immune system fight infection . ADA deficient individual cure bone marrow transplant , best result obtain fully match family donor available . In absence match related donor , transplant unrelated mismatched donor much bad outcome . There form enzyme therapy ( PEG-ADA ) ADA-deficient SCID , child receive injection purify ADA enzyme 1-2 time week . These injection allow immune system recover level protects child infection . However , injection give weekly expensive ( Â£ 125,000 - 200,000 annually ) recovery immune system sustain time . Gene therapy ADA-deficient SCID could perform introduce normal copy human ADA gene blood form stem cell patient 's bone marrow use new type gene delivery system ( trial call lentiviral vector ) . The gene correct cell transplant back patient small dose chemotherapy . These gene correct stem cell survive body make lymphocyte . In trial , determine whether gene therapy ADA-deficient SCID use lentiviral vector safe , feasible effective</brief_summary>
	<brief_title>Lentiviral Gene Therapy Adenosine Deaminase ( ADA ) Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<criteria>Diagnosis ADASCID confirm DNA sequence confirm absence &lt; 3 % ADA enzymatic activity peripheral blood ( neonate ) umbilical cord blood erythrocytes and/or leukocyte culture fetal cell derive either chorionic villus biopsy amniocentesis , prior institution PEGADA replacement therapy Patients lack fully HLAmatched family donor Patients &lt; 5 year age Parental/guardian sign informed consent Patients fully HLAmatched family donor Patients &gt; 5 year age Cytogenetic abnormality peripheral blood Evidence infection HIV1 &amp; 2 , hepatitis B , HCV Evidence active malignant disease Known sensitivity busulfan</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>